Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Slides:

Advertisements

Similar presentations

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.

Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Dr Kavita Raj Consultant Haematologist Guys and St Thomas’ Hospital.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Decreased Nuclear Receptor Activity Mediates Downregulation of Drug Metabolizing Enzymes in Chronic Kidney Disease Through Epigenetic Modulation October.

The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.

Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010.

Latency reversing agents

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):

Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.

Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.

Strategies for Targeting and Eradicating the HIV Reservoir

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.

Effects of patient tracing on estimates of lost to follow-up, mortality and retention in antiretroviral therapy programs in low-middle income countries:

I guess you think you know this story.

Histone Deacetylation Danielle Herrmann 2013 Doctor of Pharmacy Candidate University of Kansas School of Pharmacy Midwest Cancer Care.

The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.

Concepts in Basic Science and Translational Research

Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School

Plate 87 Acquired Immune Deficiency Syndrome (AIDS)

IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.

Washington D.C., USA, July 2012www.aids2012.org Viral Eradication: The Cure Agenda AIDS Research Institute (IrsiCaixa) Autonomous University of Barcelona.

I.Regulation of HIV transcription and mechanisims of latency. ii.viral – host interactions. iii.Use of lentiviruses for targeting specific cells for gene.

Overview Pediatric HIV Program & IMPAACT/ PACTG Vaccine Research Children’s National Medical Center, Washington, DC Dr.Hans ML Spiegel Director Special.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

HIV INFECTION D - preventive Medicine. HIV INFECTION LEARNING OBJECTIVES  Describe the pathophysiology of HIV infection.  Describe the principal mechanisms.

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.

KEY CONCEPT Genetics provides a basis for new medical _____________.

International perspectives on human gene editing: South Africa KEYMANTHRI MOODLEY DIRECTOR & PROFESSOR CENTRE FOR MEDICAL ETHICS & LAW DEPARTMENT OF MEDICINE.

Valproic acid in SMA Brunhilde Wirth Institute of Human Genetics University of Cologne, Germany.

Viruses Big Questions: What is a virus? How does a virus function?

Critical Care Department St. Michael’s Hospital Research Program © 2003 Critical Care Dept, St. Michael’s Hospital.

Holy Family Catholic High School 17th April 2007 Developing medicines + Immunity UNIT 11.4 Controlling infectious disease Form 10 A4.

The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:

Immune reconstitution Anjie Zhen, PhD

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

Timothy J. Henrich, MD Assistant Professor of Medicine Division of Experimental Medicine University of California San Francisco San Francisco, California.

Alan L. Landay, PhD Professor and Chairman of Immunology, Microbiology, and Medicine Rush University Medical Center Chicago, Illinois On The Road to an.

Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,

State of HIV Cure Research

HIV Cure: Current Status and Future Perspectives

Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

HIV-1 PLASMA VIRAL LOAD IN TREATMENT NAÏVE HIV-1 PATIENTS

Toward A Cure for HIV Plenary Lunch

John de Wit1,2, Dean Murphy2,3, Luxi Lal4,5,6, Jennifer Audsley5,7, Christopher K. Fairley8,9, Mark Stoove4,10, Norm Roth11, Richard Moore12, Ban K.

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang,

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Why we should ‘shock and kill’

Big Questions: What is a virus? How does a virus function?

HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir Y. Ghiglione1, M.L. Polo1,

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Li Huang Duke University, North Carolina, USA

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Aim What happens when a bacteria or virus mutates?

Nat. Rev. Neurol. doi: /nrneurol

Immunologic strategies for HIV-1 remission and eradication

Presentation transcript:

Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine, Monash University Co-head, Centre for Virology, Burnet Institute, Melbourne, Australia Amfar-IAS Satellite Meeting, 5 th IAS Conference, Rome

Gene therapy is scientifically flawed, high risk, will never get to the clinic

The problem: 1 in a million cells are latently infected

Nucleases chop up DNA – lets hope they get it 100% right! Naldini et al., Nature Genetics 2011; 12:301

Pharmacotherapy is rational, short term, toxicities that are mild and reversible, available now to test, scalable

Licensed drugs that also …..eliminate latently infected cells HDACi Vorinostat Yes Romidepsin Yes Panabinostat Entinostat Givinostat Belinostat 2 5-azacytidine Others (9) 1 Disulfiram Yes 1 Minocycline ` Yes Auranofin Yes Phase I Phase II Phase III LicensedLatency trials Methylation inhibitor Cytokine Anti-alcoholic Antibiotic Anti-rheumatic Interleukin-7 * Total number of trials listed on (July 2011) # Trials* > Latent HIV activity Latency activators Immune modulators MDX-1106 Anti PD Bryostatin PKC modulators + 22 Others Yes (1) +

Combination strategies enhance potency SAHA + Pro Viral RNA (copies/ml) NI VPA SAHA VPA + Pro Pro WHS 22 Pro = prostratin; VPA = valproic acid; SAHA = vorinostat Reuse et al., Plos One 2009 Latency activators (combination) Immune modulators +

New possibilities to enhance specificity AIDS 2009; 23(14): Plos One 2011; 6: e18270

We need a cure that is scalable, deliverable and cheap